Fundraising Fox
Emalex Biosciences
4 known investors
Find your way into Emalex Biosciences
Sign up to see every warm intro you have to Emalex Biosciences
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Emalex Biosciences team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company, created by Paragon Biosciences, advanced the asset through clinical development and was acquired by Teva Pharmaceutical Industries in 2026.
Founders & leadership
Investors · 4
How we know: Paragon Biosciences LLC's portfolio page · the company's own site · funding news · prnewswire.com · Not right? Tell us
How we know: Bain Capital Life Sciences's portfolio page · prnewswire.com · Not right? Tell us
How we know: funding news · prnewswire.com · Not right? Tell us
How we know: funding news · prnewswire.com · open dataset · 5k.vc investor directory · Not right? Tell us
Funding
SEC filings, press & company announcements$250M disclosed across 1 of 2 rounds · 2021–2022
- $250MSeries DNov 2022 · 4 sources
Bain Capital Life Sciences (lead), Fidelity Management & Research Company, Paragon Biosciences, Valor Equity Partners
Source ↗ - Undisclosed amountSeries CMar 2021Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Emalex Biosciences do?
- Emalex Biosciences is a clinical-stage biopharmaceutical company developing treatments for central nervous system disorders, including ecopipam, an investigational dopamine D1 receptor antagonist for pediatric Tourette syndrome. The company, created by Paragon Biosciences, advanced the asset through clinical development and was acquired by Teva Pharmaceutical Industries in 2026.
- Who are Emalex Biosciences's investors?
- Emalex Biosciences's investors include Paragon Biosciences LLC, Bain Capital Life Sciences, Fidelity Investments, Valor Equity Partners.
- How much funding has Emalex Biosciences raised?
- Emalex Biosciences has disclosed $250M raised across 1 of its 2 known rounds.